Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers

Table 4 Immune-histochemical results and statistical analyses of AR considered as dichotomized variable as for both cases and controls validation datasets

IHC parameter	Cut-off	Case dataset (primary ovarian lesions) (%)	Control dataset (primary ovarian lesions) (%)	p Value (Cases vs controls: IHC comparison)	OR (Cases vs controls) (CI 95%)
AR	< 1%	4/29 (13.8)	0/19 (0)	0.142
	≥ 1%	25/29 (86.2)	19/19 (100)	0.142
	< 10%	20/29 (69)	4/19 (21.1)	0.003	8,33 (2.15–32.29)
	≥ 10%	9/29 (31)	15/19 (78.9)	0.003	8,33 (2.15–32.29)
	IRS ≤ 2	24/29 (82.8)	4/19 (21.1)	< 0.001
	IRS > 2	5/29 (17.2)	15/19 (78.9)	< 0.001

ISSN: 1757-2215